Abstract
The immunotherapy based on progress in tumour immunology became a part of intensive research as a novel strategy in cancer treatment. Sipuleucel-T is the first and only medicinal product approved by the regulatory agencies in USA and Europe for the treatment of asymptomatic or minimal symptomatic castrate- refractory prostate cancer.
It represents the first product of autollogous cell therapy. This article gives a brief overview about new approaches in the cancer immunotherapy in clinical development.